Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

Saracatinib

Saracatinib inhibits c-Src and Abl at low nanomolar concentrations and exhibited high selectivity for these two enzymes against a range of kinases. It has excellent pharmacokinetic properties and is currently undergoing clinical evaluation as a possible anticancer drug.

catalogue number: S105
synonyms: AZD0530
CAS: 379231-04-6
MW: 542.04 g/mol

References
J Med Chem. 2006 Nov 2;49(22):6465-88. PMID: 17064066
Crystal structure of Src kinase in complex with saracatinib PDB: 2H8H

Prices
  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR

SB202190

SB202190 is an inhibitor of the p38 mitogen-activated protein (MAP) kinases that regulate signal transduction in response to environmental stress. It inhibits SAPK2a and SAPK2b (p38 beta2) with I50 values of 50 nM and 100 nM, respectively. It also targets BRAF and cRAF kinases. In cells, SB202190 induces cell death, with typical apoptotic features such as nucleus condensation, caspase activation and intranucleosomal DNA fragmentation.

catalogue number: S147
synonyms: -
CAS: 152121-30-7
MW: 331.34 g/mol

References
Chem Biol. 1997 Jun;4(6):423-31. PMID: 9224565
J Biol Chem. 1998 Jun 26;273(26):16415-20. PMID: 9632706
Biochem J. 2000 Oct 1;351(Pt 1):95-105. PMID: 10998351
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. PMID: 18077363

Prices
  • 5 mg - 60 EUR
  • 25 mg - 120 EUR
  • 100 mg - 360 EUR

SB203580

SB203580 is an inhibitor of the p38 mitogen-activated protein (MAP) kinases, selectively inhibiting SAPK2a and SAPK2b (p38 beta2) with I50 values of 50 nM and 500 nM, respectively. It was originally prepared as inflammatory cytokine synthesis inhibitor.

catalogue number: S148
synonyms: -
CAS: 152121-47-6
MW: 377.43 g/mol

References
Pharmacol Ther. 1999 May-Jun;82(2-3):389-97. PMID: 10454214
Biochem J. 2000 Oct 1;351(Pt 1):95-105. PMID: 10998351
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. PMID: 18077363

SCH-727965

See product D071 Dinaciclib

Prices
  • 5 mg - 160 EUR
  • 25 mg - 640 EUR
  • 100 mg - 1920 EUR

SCH900776

SCH900776 is a potent and selective inhibitor of check-point kinase 1 (CHK1) with IC50 value of 3 nM. Sensitivity of CHK2 is 500 fold lower (IC50 value of 1500 nM). Consistently with its kinase inhibitory activity, SCH900776 abrogates cell-cycle arrest induced by SN38. It interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce double strand DNA breaks and cell death in tumor cells.

catalogue number: S165
synonyms: SCH 900776, SCH-900776, MK-8776
CAS: 891494-63-6
MW: 376.25 g/mol

References
Mol Cancer Ther. 2011 Apr;10(4):591-602. PMID: 21321066
Mol Cancer Ther. 2012 Feb;11(2):427-38. PMID: 22203733

Prices
  • 25 mg - 55 EUR
  • 100 mg - 220 EUR
  • 250 mg - 440 EUR

Selumetinib

Selumetinib is a potent and selective MEK1/2 ATP-uncompetitive inhibitor with nanomolar IC50 values. It is highly active in both in vitro and in vivo tumor models. This compound is currently being investigated in clinical trials as a cancer drug.

catalogue number: S170
synonyms: AZD6244, ARRY 142886, ARRY-142886, ARRY-886
CAS: 606143-52-6
MW: 457.68 g/mol

References
Mol Cancer Ther. 2007 Jan;6(1):138-46. PMID: 17237274
Clin Cancer Res. 2007 Mar 1;13(5):1576-83. PMID: 17332304
Expert Opin Investig Drugs. 2012 Apr;21(4):531-9. PMID: 22394161

Prices
  • 5 mg - 140 EUR
  • 25 mg - 560 EUR
  • 100 mg - 1680 EUR

SNS-032

SNS-032 is a potent and selective inhibitor of cyclin-dependent kinases (CDKs) with IC50 values of 4, 62 and 38 nM for CDK9, CDK2/cyclin A and CDK7/Cyclin H, respectively. Its antiproliferative activity was established in an A2780 cellular cytotoxicity assay, in which it showed an IC50 value of 95 nM.

catalogue number: S072
synonyms: BMS-387032
CAS: 345627-80-7
MW: 380.53 g/mol

References
J Med Chem. 2004 Mar 25;47(7):1719-28. PMID: 15027863

Prices
  • 5 mg - 85 EUR
  • 25 mg - 340 EUR
  • 100 mg - 1020 EUR

Sorafenib (tosylate)

Sorafenib is a biarylurea derivative that selectively targets several receptor tyrosine kinases and Raf kinases. It has IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. It has been approved for use in the treatment of advanced renal cancer and hepatocellular carcinoma.

catalogue number: S073
synonyms: Nexavar, BAY 43-9006
CAS: 475207-59-1
MW: 637.03 g/mol (tosylate)

References
Cancer Res. 2004 Oct 1;64(19):7099-109. PMID: 15466206

Prices
  • 5 mg - 142 EUR
  • 25 mg - 568 EUR
  • 100 mg - 1704 EUR

Staurosporine

Staurosporine is a microbial alkaloid that was originally found to inhibit phospholipid/Ca(2+)dependent protein kinase (protein kinase C) in low nanomolar concentrations. Later it was proved that staurosporin is potent non-selective inhibitor of many protein kinases. It displays strong cytotoxic and proapoptotic activity in many cultured cells.

catalogue number: S149
synonyms: -
CAS: 62996-74-1
MW: 466.53 g/mol

References
Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402. PMID: 3457562
Crit Rev Oncol Hematol. 2000 May;34(2):127-35. PMID: 10799837
Methods Mol Biol. 2012;795:135-47. PMID: 21960220

Prices
  • 25 mg - 43 EUR
  • 100 mg - 129 EUR
  • 250 mg - 258 EUR

Sunitinib malate

Sunitinib is a small molecule receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity. It targets the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, and has Ki values of 9 and 8 nM for Flk-1 and PDGFR, respectively. Sunitinib has been approved for use in the treatment of kidney cancer, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors.

catalogue number: S075
synonyms: Sutent, SU-11248
CAS: 341031-54-7
MW: 532.56 g/mol (malate)

References
J Med Chem. 2003 Mar 27;46(7):1116-9. PMID: 12646019
Clin Cancer Res. 2003 Jan;9(1):327-37. PMID: 12538485